High-density lipoprotein: gene-based approaches to the prevention of atherosclerosis

References

• Gordon DJ, Rifkind BM. High-density lipoprotein--the clinical implications of recent studies. N Engl J Med 1989; 321: 1311–6.
   PubMed Web of Science ®Google Scholar
• Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). J AMA 1993; 269: 3015–23.
   PubMed Web of Science ®Google Scholar
• Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101: 207–13.
   PubMed Web of Science ®Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9.
   PubMed Web of Science ®Google Scholar
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349–57.
   PubMed Web of Science ®Google Scholar
• Schaefer EJ, Zech LA, Schwartz DE, Brewer HBJr. Coronary heart disease prevalence and other clinical features in familial high-density lipoprotein deficiency (Tangier disease). Ann Intern Med 1980; 93: 261–6.
   PubMed Web of Science ®Google Scholar
• Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997; 17: 107–13.
   PubMed Web of Science ®Google Scholar
• Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8–15.
   PubMed Web of Science ®Google Scholar
• Hasty AH, Linton MF, Brandt SJ, Babaev VR, Gleaves LA, Fazio S. Retroviral gene therapy in ApoE-deficient mice: ApoE expression in the artery wall reduces early foam cell lesion formation. Circulation 1999; 99: 2571–6.
   Google Scholar
• Kozarsky KF, Donahee MH, Glick JM, Krieger M, Rader DJ. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler Thromb Vasc Biol 2000; 20: 721–7.
   PubMed Web of Science ®Google Scholar
• Tangirala RK, Tsukamoto K, Chun SH, Usher D, Pure E, Rader DJ. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 1999; 100: 1816–22.
   PubMed Web of Science ®Google Scholar
• Tsukamoto K, Tangirala R, Chun SH, Pure E, Rader DJ. Rapid regression of atherosclerosis induced by liver-directed gene transfer of ApoE in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 1999; 19: 2162–70.
   PubMed Web of Science ®Google Scholar
• Desurmont C, Caillaud JM, Emmanuel F, Benoit P, Fruchart JC, Castro G, et at. Complete atherosclerosis regression after human ApoE gene transfer in ApoE-deficient/nude mice. Arterioscler Thromb Vasc Biol 2000; 20: 435–42.
   PubMed Web of Science ®Google Scholar
• Benoit P, Emmanuel F, Caillaud JM, Bassinet L, Castro G, Gallix P, et al. Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models. Circu-lation 1999; 99: 105–10.
   PubMed Web of Science ®Google Scholar
• Kane J. Structure, and function of the plasma lipoproteins and their receptors. In: Fuster V, Ross R, Topol E, eds. Atherosclerosis and coronary artery disease. Vol 1. Philadel-phia, PA: Lippincott-Raven; 1996: 89–103.
   Google Scholar
• Tall A, Breslow J. Plasma high-density lipoproteins and atherogenesis. In: Fuster V, Ross R, Topol E, eds. Athero-sclerosis and coronary artery disease. Vol 1. Philadelphia, PA: Lippincott-Raven; 1996: 105–362.
   Google Scholar
• Banka CL. High density lipoprotein and lipoprotein oxi-dation. Curr Opin Lipidol 1996; 7: 139–42.
   PubMed Web of Science ®Google Scholar
• Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 1996; 20: 707–27.
   PubMed Web of Science ®Google Scholar
• Barter PJ, Rye KA. High density lipoproteins and coronary heart disease. Atherosclerosis 1996; 121: 1–12.
   PubMed Web of Science ®Google Scholar
• Wang N, Weng W, Breslow JL, Tall AR. Scavenger receptor BI (SR-BI) is up-regulated in adrenal gland in apolipoprotein A-I and hepatic lipase knock-out mice as a response to depletion of cholesterol stores. In vivo evidence that SR-BI is a functional high density lipoprotein receptor under feed-back control. J Biol Chem 1996; 271: 21001–4.
   Google Scholar
• Kozyraki R, Fyfe J, Kristiansen M, Gerdes C, Jacobsen C, Cui S, et al. The intrinsic factor-vitamin B12 receptor, cubilin, is a high-affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein. Nat Med 1999; 5: 656–61.
   PubMed Web of Science ®Google Scholar
• Young SG, Fielding CJ. The ABCs of cholesterol efflux. Nat Genet 1999; 22: 316–8.
   PubMed Web of Science ®Google Scholar
• Brinton EA, Eisenberg S, Breslow JL. Elevated high density lipoprotein cholesterol levels correlate with decreased apolipoprotein A-I and A-II fractional catabolic rate in women. J Clin Invest 1989; 84: 262–9.
   PubMed Web of Science ®Google Scholar
• Rader DJ, Maugeais C. Genes influencing HDL metabolism: new perspectives and implications for atherosclerosis pre-vention. Mol Med Today 2000; 6: 170–5.
   PubMedGoogle Scholar
• Li H, Reddick RL, Maeda N. Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice. Arterioscler Thromb 1993; 13: 1814–21.
   Google Scholar
• Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein Al. Nature 1991; 353: 265–7.
   PubMed Web of Science ®Google Scholar
• Paszty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein Al transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest 1994; 94: 899–903.
   PubMed Web of Science ®Google Scholar
• Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A 1994; 91: 9607–11.
   Google Scholar
• Duverger N, Kruth H, Emmanuel F, Caillaud JM, Viglietta C, Castro G, et at. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation 1996; 94: 713–7.
   PubMed Web of Science ®Google Scholar
• Johnson WJ, Mahlberg FH, Rothblat GH, Phillips MC. Cholesterol transport between cells and high-density lipo-proteins. Biochim Biophys Acta 1991; 1085: 273–98.
   PubMed Web of Science ®Google Scholar
• Weng W, Brandenburg NA, Zhong S, Halkias J, Wu L, Jiang XC, et al. ApoA-II maintains HDL levels in part by inhibition of hepatic lipase. Studies In apoA-II and hepatic lipase double knockout mice. J Lipid Res 1999; 40: 1064–70.
   Google Scholar
• Huang Y, von Eckardstein A, Wu S, Assmann G. Cholesterol efflux, cholesterol esterification, and cholesteryl ester transfer by LpA-I and LpA-I/A-II in native plasma. Arterioscler Thromb Vasc Biol 1995; 15: 1412–8.
   PubMed Web of Science ®Google Scholar
• Deeb SS, Takata K, Peng RL, Kajiyama G, Albers JJ. A splice-junction mutation responsible for familial apolipo-protein A-II deficiency. Am] Hum Genet 1990; 46: 822–7.
   Google Scholar
• Weng W, Breslow JL. Dramatically decreased high density lipoprotein cholesterol, increased remnant clearance, and insulin hypersensitivity in apolipoprotein A-II knockout mice suggest a complex role for apolipoprotein A-II in atherosclerosis susceptibility. Proc Natl Acad Sci U S A 1996; 93: 14788–94.
   PubMedGoogle Scholar
• Warden CH, Hedrick CC, Qiao JH, Castellani LW, Lusis AJ. Atherosclerosis in transgenic mice overexpressing apolipo-protein A-II. Science 1993; 261: 469–72.
   PubMedGoogle Scholar
• Ohta T, Fidge NH, Nestel PJ. Studies on the in vivo and in vitro distribution of apolipoprotein A-IV in human plasma and lymph. J Clin Invest 1985; 76: 1252–60.
   Google Scholar
• Weinstock PH, Bisgaier CL, Hayek T, Aalto-Setala K, Sehayek E, Wu L, et al. Decreased HDL cholesterol levels but normal lipid absorption, growth, and feeding behavior in apolipoprotein A-TV knockout mice. J Lipid Res 1997; 38: 1782–94.
   PubMedGoogle Scholar
• Duverger N, Tremp G, Calllaud JM, Emmanuel F, Castro G, Fruchart JC, et al. Protection against atherogenesis in mice mediated by human apolipoprotein A-IV. Science 1996; 273: 966–8.
   PubMedGoogle Scholar
• Kuivenhoven JA, Pritchard H, Hill J, Frohlich J, Assmann G, Kastelein J. The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res 1997; 38: 191–205.
   PubMed Web of Science ®Google Scholar
• Wiebusch H, Cullen P, Owen JS, Collins D, Sharp PS, Funke H, et at. Deficiency of lecithin:cholesterol acyltransferase due to compound heterozygosity of two novel mutations (Gly33Arg and 30 bp ins) in the LCAT gene. Hum Mol Genet 1995; 4: 143–5.
   Google Scholar
• Sakai N, Vaisman BL, Koch CA, Hoyt RF, Jr, Meyn SM, Talley GD, et at. Targeted disruption of the mouse lecithin:cholesterol acyltransferase (LCAT) gene. Generation of a new animal model for human LCAT deficiency. J Biol Chem 1997; 272: 7506–10.
   Google Scholar
• Berard AM, Foger B, Remaley A, Shamburek R, Vaisman BL, Talley G, et al. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nat Med 1997; 3: 744–9.
   PubMed Web of Science ®Google Scholar
• Hoeg JM, Santamarina-Fojo S, Berard AM, Cornhill JF, Herderick EE, Feldman SH, et at. Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc Nat! Acad Sci USA 1996;93: 11448–53.
   PubMed Web of Science ®Google Scholar
• Foger B, Chase M, Amar MJ, Vaisman BL, Shamburek RD, Paigen B, et al. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase trans-genic mice. J Biol Chem 1999; 274: 36912–20.
   PubMed Web of Science ®Google Scholar
• Watson AD, Berliner JA, Hama SY, La Du BN, Fault KF, Fogelman AM, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the bio-logical activity of minimally oxidized low density lipo-protein. J Clin Invest 1995; 96: 2882–91.
   PubMed Web of Science ®Google Scholar
• Shih DM, Xia YR, Wang XP, Miller E, Castellani LW, Subbanagounder G, et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem 2000; 275: 17527–35.
   PubMed Web of Science ®Google Scholar
• Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, et at. Mice lacking serum paraoxonase are susceptible to organo-phosphate toxicity and atherosclerosis. Nature 1998; 394: 284–7.
   PubMed Web of Science ®Google Scholar
• Antikainen M, Murtomäki S, Syvänne M, Pahlman R, Tahvanainen E, Jauhiainen M, et al. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest 1996; 98: 883–5.
   PubMed Web of Science ®Google Scholar
• Ruiz J, Blanche H, James RW, Garin MC, Vaisse C, Charpentier G, et al. Gln-Arg192 polymorphism of para-oxonase and coronary heart disease in type 2 diabetes. Lancet 1995; 346: 869–72.
   PubMed Web of Science ®Google Scholar
• Inazu A, Brown ML, Hester CB, Agellon LB, Koizumi J, Takata K, et at. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990; 323: 1234–8.
   PubMed Web of Science ®Google Scholar
• Bruce C, Sharp DS, Tall AR. Relationship of HDL and coronary heart disease to a common amino acid poly-morphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia. J Lipid Res 1998; 39: 1071–8.
   PubMed Web of Science ®Google Scholar
• Guyard-Dangremont V, Desrumaux C, Gambert P, Lallemant C, Lagrost L. Phospholipid and cholesteryl ester transfer activities in plasma from 14 vertebrate species. Relation to atherogenesis susceptibility. Comp Biochem Physiol B Biochem Mol Biol 1998; 120: 517–25.
   Google Scholar
• Plump AS, Masucci-Magoulas L, Bruce C, Bisgaier CL, Breslow JL, Tall AR. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol 1999; 19: 1105–10.
   PubMed Web of Science ®Google Scholar
• Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000; 406: 203–7.
   PubMed Web of Science ®Google Scholar
• Jauhiainen M, Metso J, Pahlman R, Blomqvist S, van Tot A, Ehnholm C. Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem 1993; 268: 4032–6.
   PubMed Web of Science ®Google Scholar
• Jiang XC, Bruce C, Mar J, Lin M, Ji Y, Francone OL, et al. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest 1999; 103: 907–14.
   PubMedGoogle Scholar
• Albers JJ, Tu AY, Paigen B, Chen H, Cheung MC, Marcovina SM. Transgenic mice expressing human phos-pholipid transfer protein have increased HDL/non-HDL cholesterol ratio. Int J Clin Lab Res 1996; 26: 262–7.
   PubMedGoogle Scholar
• van Haperen R, van To! A, Vermeulen P, Jauhiainen M, van Gent T, van den Berg P, et al. Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arterioscler Thromb Vasc Biol 2000; 20: 1082–8.
   PubMedGoogle Scholar
• Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 1999; 22: 352–5.
   PubMed Web of Science ®Google Scholar
• Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 1999; 22: 347–51.
   PubMed Web of Science ®Google Scholar
• Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 1999; 22: 336–45.
   PubMed Web of Science ®Google Scholar
• Orso E, Broccardo C, Kaminski WE, Bottcher A, Liebisch G, Drobnik W, et al. Transport of lipids from golgi to plasma membrane is defective in tangier disease patients and Abel-deficient mice. Nat Genet 2000; 24: 192–6.
   PubMed Web of Science ®Google Scholar
• Glass C, Pittman RC, Weinstein DB, Steinberg D. Dis-sociation of tissue uptake of cholesterol ester from that of apoprotein A-I of rat plasma high density lipoprotein: selective delivery of cholesterol ester to liver, adrenal, and gonad. Proc Nat! Acad Sci U S A 1983; 80: 5435–9.
   PubMed Web of Science ®Google Scholar
• Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996; 271: 518–20.
   PubMed Web of Science ®Google Scholar
• Acton S, Osgood D, Donoghue M, Corella D, Pocovi M, Cenarro A, et al. Association of polymorphisms at the SR-BI gene locus with plasma lipid levels and body mass index in a white population. Arterioscier Thromb Vasc Biol 1999; 19: 1734–43
   Web of Science ®Google Scholar
• Trigatti B, Rayburn H, Vinals M, Braun A, Miettinen H, Penman M, et al. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular patho-physiology. Proc Nat! Acad Sci U S A 1999; 96: 9322–7.
   PubMed Web of Science ®Google Scholar
• Huszar D, Varban ML, Rinninger F, Feeley R, Arai T, Fairchild-Huntress V, et al. Increased LDL cholesterol and atherosclerosis in LDL receptor-deficient mice with attenu-ated expression of scavenger receptor Bl. Arterioscler Thromb Vasc Biol 2000; 20: 1068–73.
   PubMed Web of Science ®Google Scholar
• Arai T, Wang N, Bezouevski M, Welch C, Tall AR. Decreased atherosclerosis in heterozygous low density lipo-protein receptor-deficient mice expressing the scavenger receptor BI transgene. J Biol Chem 1999; 274: 2366–71.
   PubMed Web of Science ®Google Scholar
• Ji Y, Wang N, Ramakrishnan R, Sehayek E, Huszar D, Breslow JL, et al. Hepatic scavenger receptor BI promotes rapid clearance of high density lipoprotein free cholesterol and its transport into bile. J Biol Chem 1999; 274: 33398–402.
   PubMed Web of Science ®Google Scholar
• Hammad SM, Stefansson S, Twal WO, Drake CJ, Fleming P, Remaley A, et al. Cubilin, the endocytic receptor for intrinsic factor-vitamin B(12) complex, mediates high-density lipoprotein holoparticle endocytosis. Proc Nat! Acad Sci USA 1999; 96: 10158–63.
   PubMed Web of Science ®Google Scholar
• Kopfler WP, Willard M, Betz T, Willard JE, Gerard RD, Meidell RS. Adenovirus-mediated transfer of a gene en-coding human apolipoprotein A-I into normal mice in-creases circulating high-density lipoprotein cholesterol. Circulation 1994; 90: 1319–27.
   PubMed Web of Science ®Google Scholar
• Seguret-Mace S, Latta-Mahieu M, Castro G, Luc G, Fruchart JC, Rubin E, et al. Potential gene therapy for lecithin-cholesterol acyltransferase (LCAT)-deficient and hypoalphalipoproteinemic patients with adenovirus-medi-ated transfer of human LCAT gene. Circulation 1996; 94: 2177–84.
   Google Scholar
• Ehnholm S, van Dijk KW, van 't Hof B, van der Zee A, Olkkonen VM, Jauhiainen M, et al. Adenovirus mediated overexpression of human phospholipid transfer protein alters plasma HDL levels in mice. J Lipid Res 1998; 39: 1248–53.
   PubMed Web of Science ®Google Scholar